The sulphydryl containing ACE inhibitor Zofenoprilat protects coronary endothelium from Doxorubicin-induced apoptosis

Pharmacological Research

Volumn 76, Issue , 2013, Pages 171-181

  Monti, Martina ^a   Terzuoli, Erika ^a   Ziche, Marina ^a   Morbidelli, Lucia ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Apoptosis; Cardiotoxicity; Coronary endothelium; Doxorubicin; ERK1 2; Hydrogen sulfide; P53; Tumor; Zofenoprilat

Indexed keywords

CASPASE 3; CYSTATHIONINE GAMMA LYASE; DOXORUBICIN; ENALAPRILAT; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR; LISINOPRIL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; ZOFENOPRILAT;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM; ENZYME ACTIVATION; ENZYME ACTIVITY; HEART MUSCLE CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

APOPTOSIS; CARDIOTOXICITY; CORONARY ENDOTHELIUM; DOXORUBICIN; ERK1/2; HYDROGEN SULFIDE; P53; TUMOR; ZOFENOPRILAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CAPTOPRIL; CATTLE; CELL LINE; CELL LINE, TUMOR; CORONARY VESSELS; DOXORUBICIN; ENDOTHELIUM; ENDOTHELIUM, VASCULAR; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84883855340     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2013.08.003     Document Type: Article

References (38)

1. E.T.H. Yeh, and C.L. Bickford Cardiovascular complications of cancer therapy. Incidence, pathogenesis, diagnosis, and management J Am Coll Cardiol 53 2009 2231 2247
2. T. Force, and K.L. Kolaja Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes Nat Rev Drug Discov 10 2011 111 126
3. A. Zambelli, M.G. Della Porta, E. Eleuteri, L. De Giuli, O. Catalano, and C. Tondini Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues Breast 20 2011 176 183
4. T. Murata, H. Yamawaki, R. Yoshimoto, M. Hori, K. Sato, and H. Ozaki Chronic effect of Doxorubicin on vascular endothelium assessed by organ culture study Life Sci 69 2001 2685 2695 (Pubitemid 32972298)
5. A.H. Blaes, P. Gaillard, B.A. Peterson, D. Yee, and B. Virning Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy Breast Cancer Res Treat 122 2010 585 590
6. B. Kalyanaraman, J. Joseph, S. Kalivendi, S. Wang, E. Konorev, and S. Kotamraju Doxorubicin-induced apoptosis: implications in cardiotoxicity Mol Cell Biochem 234-235 2002 119 124 (Pubitemid 34777848)
7. S. Wu, Y.S. Ko, M.S. Teng, Y.L. Ko, L.A. Hsu, and C. Hsueh Adriamycin-induced cardiomyocyte and endothelial cell apoptosis: in vitro and in vivo studies J Mol Cell Cardiol 34 2002 1595 1607 (Pubitemid 35454475)
8. Y.W. Zhang, J. Shi, Y.J. Li, and L. Wei Cardiomyocyte death in Doxorubicin-induced cardiotoxicity Arch Immunol Ther Exp (Warsz) 57 2009 435 445
9. D. Cardinale, A. Colombo, M.T. Sandri, G. Lamantia, N. Colombo, and M. Civelli Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 114 2006 2474 2481 (Pubitemid 44901520)
10. M. Iqbal, K. Dubey, T. Anwer, A. Ashish, and K.K. Pillai Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats Pharmacol Rep 60 2008 382 390
11. P. Georgakopoulos, P. Roussou, E. Matsakas, A. Karavidas, N. Anagnostopoulos, and T. Marinakis Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up Am J Hematol 85 2010 894 896
12. G. Sacco, M. Bigioni, S. Evangelista, C. Goso, S. Mancini, and C.A. Maggi Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat Eur J Pharmacol 414 2001 71 78 (Pubitemid 32174877)
13. G. Sacco, M. Bigioni, G. Lopez, S. Evangelista, S. Manzini, and C.A. Maggi ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat Vascul Pharmacol 50 2009 166 170
14. E. Bozcali, D.B. Dedeoglu, V. Karpuz, O. Suzer, and H. Karpuz Cardioprotective effects of zofenopril, enalapril and valsartan against ischemia/reperfusion injury as well as doxorubicin cardiotoxicity Acta Cardiol 671 2012 87 96
15. L. Cominacini, A. Pasini, U. Garbin, S. Evangelista, A.E. Crea, and D. Tagliacozzi Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species Am J Hypertens 15 2002 891 895 (Pubitemid 35168428)
16. S. Evangelista, and S. Manzini Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril J Int Med Res 33 2005 42 54 (Pubitemid 40201935)
17. A.W. Scribner, J. Loscalzo, and C. Napoli The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress Eur J Pharmacol 482 2003 95 99 (Pubitemid 37505931)
18. S. Donnini, R. Solito, A. Giachetti, H.J. Granger, M. Ziche, and L. Morbidelli Fibroblast growth factor-2 mediates Angiotensin-converting enzyme inhibitor-induced angiogenesis in coronary endothelium J Pharmacol Exp Ther 319 2006 515 522
19. S. Donnini, E. Terzuoli, M. Ziche, and L. Morbidelli Sulfhydryl angiotensin converting enzyme inhibitor promotes endothelial cell survival through nitric oxide synthase, fibroblast growth factor-2 and telomerase cross-talk J Pharmacol Exp Ther 332 2010 776 784
20. R.F. Greene, J.M. Collins, J.F. Jenkins, J.L. Speyer, and C.E. Myers Plasma pharmacokinetics of Adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols Cancer Res 43 1983 3417 3421 (Pubitemid 13061607)
21. M.E. Schelling, C.J. Meininger, J.R. Hawker Jr., and H.J. Granger Venular endothelial cells from bovine heart Am J Physiol 254 1988 H1211 H1217
22. L. Morbidelli, A. Pyriochou, S. Filippi, I. Vasileiadis, C. Roussos, and Z. Zhou The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability Am J Physiol Regul Integr Comp Physiol 298 3 2010 R824 R832
23. S. Donnini, F. Finetti, R. Solito, E. Terzuoli, A. Sacchetti, and L. Morbidelli EP2 prostanoid receptor promotes squamous cell carcinoma growth through epidermal growth factor receptor transactivation and iNOS and ERK1/2 pathways FASEB J 21 2007 2418 2430 (Pubitemid 47230672)
24. M. Monti, S. Donnini, A. Giachetti, D. Mochly-Rosen, and M. Ziche deltaPKC inhibition or epsilonPKC activation repairs endothelial vascular dysfunction by regulating eNOS post-translational modification J Mol Cell Cardiol 48 2010 746 756
25. M. Galderisi, and O. de Divitiis Risk factor-induced cardiovascular remodeling and the effects of angiotensin-converting enzyme inhibitors J Cardiovasc Pharmacol 51 2008 523 531
26. D. Duquaine, G.A. Hirsch, A. Chakrabarti, Z. Han, C. Kehrer, and R. Brook Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase Vasc Med 8 2003 101 107 (Pubitemid 37168251)
27. J. Liu, W. Mao, B. Ding, and C-S. Liang ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes Am J Physiol Heart Circ Physiol 295 2008 H1956 H1963
28. C. Coletta, A. Papapetropoulos, K. Erdelyi, G. Olah, K. Módis, and P. Panopoulos Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation Proc Natl Acad Sci U S A 109 2012 9161 9166
29. R.C. Zanardo, V. Brancaleone, E. Distrutti, S. Fiorucci, G. Cirino, and J.L. Wallace Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation FASEB J 20 2006 2118 2120
30. J.W. Elrod, J.W. Calvert, J. Morrison, J.E. Doeller, D.W. Kraus, and L. Tao Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function Proc Natl Acad Sci USA 104 2007 15560 15565 (Pubitemid 47502956)
31. P. Menna, O.G. Paz, M. Chello, E. Covino, E. Salvatorelli, and G. Minotti Anthracycline cardiotoxicity Expert Opin Drug Saf 11 2012 S21 S36
32. R. Zucchi, S. Ghelardoni, and S. Evangelista Biochemical basis of ischemic heart injury and cardioprotective interventions Curr Med Chem 14 2007 1619 1637 (Pubitemid 47010152)
33. R. Guo, J. Lin, W. Xu, N. Shen, L. Mo, and C. Zhang Hydrogen sulfide attenuates doxorubicin induced cardiotoxicity by inhibition of the p38 MAPK pathway in H9c2 cells Int J Mol Med 31 2013 644 650
34. M. Wang, Z. Guo, and S. Wang The effect of certain conditions in the regulation of cystathionine γ-lyase by exogenous hydrogen sulfide in mammalian cells Biochem Genet 51 2013 503 513
35. A. Subissi, S. Evangelista, and A. Giachetti Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties Cardiovasc Drug Rev 2 1999 115 133 (Pubitemid 29485360)
36. R.K. Jain Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy Science 307 2005 58 62 (Pubitemid 40093472)
37. S. Goel, D.G. Duda, L. Xu, L.L. Munn, Y. Boucher, and D. Fukumura Normalization of vasculature for treatment of cancer and other diseases Physiol Rev 91 2011 1071 1121
38. T.D.L. Brutsaer Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity Physiol Rev 83 2003 59 115